Astrazeneca (AZN) Profit After Tax (2009 - 2026)

Astrazeneca has reported Profit After Tax for 18 years, with the latest figure at $2.5 billion in Q2 2026.

• On a quarterly basis, Profit After Tax rose 2.45% year-over-year to $2.5 billion in Q2 2026; TTM through Jun 2026 was $10.5 billion, a 25.91% increase from a year earlier, with the FY2025 full-year figure at $10.2 billion, up 45.33% from the prior year.
• Profit After Tax was $2.5 billion for Q2 2026 at Astrazeneca, down from $3.1 billion in the prior quarter.
• The five-year high for Profit After Tax was $5.0 billion in Q4 2023, with the low at $360.0 million in Q2 2022.
• Average Profit After Tax over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 75.16% in 2022, then surged 454.55% in 2023.
• Over 5 years, Profit After Tax stood at $902.0 million in 2022, then soared by 454.55% to $5.0 billion in 2023, then slumped by 70.01% to $1.5 billion in 2024, then jumped by 55.27% to $2.3 billion in 2025, then climbed by 7.69% to $2.5 billion in 2026.
• The last three Profit After Tax figures came in at $2.5 billion (Q2 2026), $3.1 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.